Loss of tumour suppressor p16 expression in initial stages of oral oncogenesis

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 979-984

  Vairaktaris, Eleftherios ^a   Yapijakis, Christos ^a   Psyrri, Amanda ^a   Spyridonidou, Sofia ^a   Yannopoulos, Athanasios ^a   Lazaris, Andreas ^a   Vassiliou, Stavros ^a   Ferekidis, Eleftherios ^a   Vylliotis, Antonis ^a   Nkenke, Emeka ^b   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Hamster; Immunohistochemistry; Oral squamous cell carcinoma; p16

Indexed keywords

CARCINOGEN; MONOCLONAL ANTIBODY; PROTEIN P16;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; HAMSTER; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE SILENCING; IMMUNOHISTOCHEMISTRY; MALE; MESOCRICETUS; MOUTH NEOPLASMS;

EID: 34247161466     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rodrigues VC, Moss SM and Tuomainen H: Oral cancer in the UK: to screen or not screen. Oral Oncol 34: 454-465, 1998.
2. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
3. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, Olsen JH and Wennerberg J: Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer 101: 95-99, 2002.
4. Ponder BA: Cancer genetics. Nature 411: 336-341, 2001.
5. Serrano M: The Tumour Suppressor Protein p16INK4a. Exp Cell Res 237: 7-13, 1997.
6. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
7. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
8. Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW: Oncogenic ras Provokes Premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602, 1997.
9. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y and Wong DT: Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 13: 51-61, 2002.
10. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelaman WN, Lotan R, Hong WK and Mao L: Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14: 1799-1803, 1997.
11. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC and Weghorst CM: Alterations of p16INK4a and p14ARF in patients with severe oral epithelial dysplasia. Cancer Res 62: 5295-5300, 2002.
12. Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, Beleites E, Claussen U and von Eggeling F: Tumour suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med 4: 61-65, 1999.
13. Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y and Matsumura T: Alterations of Rb, p16INK4A and cyclin D1 in the tumourigenesis of oral squamous cell carcinomas. Cancer Lett 160: 3-8, 2000.
14. Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB and Srivatsan ES: Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumours. Laryngoscope 112: 472-481, 2002.
15. Muscarella P, Knobloch TJ, Ulrich AB, Casto BC, Moniaux N, Wittel UA, Melvin WS, Pour PM, Song H, Gold B, Batra SK and Weghorst CM: Identification and sequencing of the Syrian Golden hamster (Mesocricetus auratus) p16 (INKAa) and p15 (INK4b) cDNAs and their homozygous gene deletion in cheek pouch and pancreatic tumour cells. Gene 278(1-2): 235-243, 2001.
16. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, Spyridonidou S, Lazaris AC, Mourouzis C, Kokkori A, Moulavassili P, Perrea D, Donta I, Yapijakis C and Patsouris E: Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol 42(5): 540-550, 2006.
17. Papakosta V, Vairaktaris E, Vylliotis A, Derka S, Nkenke E, Vassiliou S, Lazaris A, Mourouzis C, Rallis G, Spyridonidou S, Anagnostopoulou S, Perrea D, Donta I, Yapijakis C and Patsouris E: The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis. Anticancer Res 26(4B): 2957-2962, 2006.
18. Vairaktaris E, Papageorgiou G, Derka S, Moulavassili P, Nkenke E, Kessler P, Vassiliou S, Papakosta V, Spyridonidou S, Vylliotis A, Lazaris AC, Anagnostopoulou S, Mourouzis C, Yapijakis C and Patsouris E: Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis. J Cancer Res Clin Oncol 133(4): 227-233, 2007.
19. Chang KW, Saraj S, Lin SC, Tsai PI and Solt D: p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21(7): 1441-1451, 2000.
20. Balasenthil S, Saroja M, Ramachandran CR and Nagini S: Of humans and hamsters: comparative analysis of lipid peroxodation, glutathione and glutathione-dependent enzymes during oral carcinogenesis. Br J Oral Maxillofac Surg 38: 267-270, 2000.
21. Tang XH, Knudsen B, Bemis D, Tickoo S and Gudas Lf: Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 10: 301-313, 2004.
22. Li Y, Nichols MA, Shay JW and Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product Rb. Cancer Res 54(23): 6078-6082, 1994.
23. Pande P, Mathur M, Shukla NK and Ralhan R: Rb and p16 protein alterations in human oral tumourigenesis. Oral Oncol 34: 396-403, 1998.
24. INK4a in dysplastic lesions of the oral cavity. Mod Pathol 19(10): 1310-1316, 2006.
25. Gonzales-Moles MA, Rodriguez-Archilla A, Ruiz-Avila I, Martinez AB, Morales-Garcia P and Gonzalez-Moles S: p16 Expression in squamous carcinomas of the tongue. Onkologie 25(5): 433-436, 2002.
26. Shintani S, Mihara M, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T and Wong DT: Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 38: 235-243, 2002.
27. Huang MJ, Yeh KT, Shih HC, Wang YF, Lin TH, Chang JY, Shih MC and Chang JG: The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int J Mol Med 10(5): 551-554, 2002.
28. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC and Weghorst CM: Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 62(18): 5295-5300, 2002.
29. Yakushiji T, Noma H, Shibahara T, Arai K, Yamamoto N, Tanaka C, Uzawa K and Tanzawa H: Analysis of a role for p16/CDKN2 expression and methylation patterns in human oral squamous cell carcinoma. Bull Tokyo Dent Coll 42(3): 159-168, 2001.
30. Nakahara Y, Shintani S, Mihara M, Matsumura T and Hamakawa H: High frequency methylation of p16INK4A gene during 4-nitroquinoline-1-oxide- induced rat tongue carcinogenesis. Oncol Rep 12(1): 101-106, 2004.